Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 17Gastrointestinal 4Tumor-Agnostic 3Other solid neoplasm 3Head & Neck 3Gynecologic 2Dermatologic 2Sarcoma 1Plasma cell 1Genitourinary 1CNS 1

Conditions

Melanoma 2Uveal Melanoma 1Breast Neoplasms 1

Interventions

pembrolizumab 100Nivolumab 69Cyclophosphamide 67Ipilimumab 66fludarabine 34aldesleukin 29fludarabine phosphate 28Vemurafenib 28Interleukin-2 26trametinib 20Biopsy 20dabrafenib 17Radiotherapy 16Temozolomide 15Cisplatin 15Magnetic Resonance Spectroscopy 14Gemcitabine 14Filgrastim 14atezolizumab 13Specimen Handling 13Carboplatin 13CTLA-4 Antigen 13spartalizumab 12romidepsin 12Paclitaxel 12Bortezomib 11poly ICLC 10cobimetinib 10Peripheral Blood Stem Cell Transplantation 10Oxaliplatin 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Alpelisib × Dermatologic × Clear all
NCT06545682 2026-04-16

Phase Ib Study of AlpeliSib With PEmbroLizumab in Patients With mEtastatic Breast caNcer or melanomA (SELENA)

M.D. Anderson Cancer Center

Phase 1 Recruiting
50 enrolled
BreastDermatologic

Breast Neoplasms, Melanoma

NCT02273219 2023-08-15

Trial of AEB071 in Combination With BYL719 in Patients With Melanoma

Columbia University

Phase 1 Completed
30 enrolled
Dermatologic

Uveal Melanoma, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡